Recent News

Novel Oral PIM Kinase Inhibitor Under Study in Resistant Multiple Myeloma

Newly Diagnosed Myeloma: Novel Scenario for Carfilzomib-Linked Thrombotic Microangiopathy

AACR 2021: Is Novel IKZF1/3 Degrader Active Against Multiple Myeloma?

Isatuximab/Pomalidomide/Dexamethasone in Myeloma: Is Prescreening Patients for Biomarkers Warranted?

ICER Releases Evidence Report on BCMA Therapies for Multiple Myeloma

Expert European Panel Provides Clinical Practice Guidelines for Multiple Myeloma

Use of Generic Pomalidomide in India for Resistant Multiple Myeloma

Daratumumab-Based Therapy for Myeloma: Patient-Reported Outcomes From CASTOR Trial

FDA Approves Isatuximab-irfc Combination Therapy for Multiple Myeloma

FDA Approves First Cell-Based Gene Therapy for Multiple Myeloma

Early Access Treatment Protocol of Daratumumab in European and Russian Patients With Resistant Myeloma

Combination Regimens for Transplant-Ineligible Myeloma: From the Canadian Myeloma Research Group

Avelumab Plus Hypofractionated Radiotherapy for Resistant Multiple Myeloma

Cardiac Repolarization After Daratumumab Monotherapy for Smoldering Multiple Myeloma

Idecabtagene Vicleucel Under Study in Relapsed and Refractory Multiple Myeloma

Isolated Radiotherapy for Myeloma Lesions of the Cervical Spine: Case Report

Collaborative Initiative Offers Recommendations to Improve Diversity in Myeloma Trials

Long-Term Outcomes With Standard-of-Care Strategy in Multiple Myeloma

Melphalan Flufenamide Receives Accelerated Approval for Resistant Multiple Myeloma

Taking on Myeloma and Prostate Cancer: A Man Named Steele

TCT 2021: Is Idecabtagene Vicleucel Safe for Elderly Patients With Resistant Myeloma?

Does a Patient’s Race Affect Access to IV Bisphosphonates in Multiple Myeloma?

Ixazomib Plus Standard Therapy for Myeloma: Outcomes in Routine Clinical Practice

Selinexor Triplet Under Study in Resistant Multiple Myeloma

Continued Trials for Iberdomide in Combination Therapy for Resistant Myeloma

Seeking the Right Dose of Immunoconjugate Combination in Resistant Myeloma

Corneal Changes With Antibody-Drug Conjugate in Myeloma: Mechanism Remains Unknown

Ixazomib Plus Standard Therapy in Transplant-Ineligible Patients With Myeloma

Cyclophosphamide Plus Weekly Carfilzomib and Dexamethasone in Resistant Myeloma

Carfilzomib-Based Therapy for High-Risk Smoldering Multiple Myeloma

Is Hypercalcemia Linked to Poor Survival in Newly Diagnosed Multiple Myeloma?

Investigational Immunotherapy Focus of Phase I Trial in Resistant Myeloma

ASH 2020: Intravenous and Subcutaneous Teclistamab for Resistant Multiple Myeloma

Selinexor Approved by FDA for Refractory or Relapsed Multiple Myeloma

ASH 2020: Ciltacabtagene Autoleucel Under Study in Resistant Myeloma

Daratumumab Plus Pomalidomide and Low-Dose Dexamethasone in Myeloma: Immune-Mediated Cytotoxicity

ASH 2020: Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone in Resistant Myeloma

Are Carfilzomib-Based Regimens Safe and Effective for Frail Patients With Myeloma?

ASH 2020: Novel Immunotherapy Plus Chemotherapy in Resistant Multiple Myeloma

ASH 2020: BCMA-Targeted Antibody-Drug Conjugate in Resistant Multiple Myeloma

Myeloma and COVID-19: Dana-Farber and Quest Diagnostics Collaborate on IMPACT Study

Trends in Myeloma by Age: Treatment and Outcome Disparities Explored

ARROW Trial: Once- or Twice-Weekly Carfilzomib Plus Dexamethasone in Myeloma

Ixazomib Plus Lenalidomide/Dexamethasone for Transplant-Ineligible Patients With Myeloma

ASTRO 2020: Low-Dose Radiotherapy for Painful Osseous Lesions in Patients With Myeloma

ASTRO 2020: U.S. Trends in Use of Palliative Radiotherapy for Myeloma

Novel Peptide-Drug Conjugate Plus Dexamethasone Under Study in Resistant Myeloma